The ZFAS1/DDX21/POLR1B signaling regulation axis may also be a new biomarker for targeted CRC treatment, where ZFAS1 knockdown dramatically reduced cancer cell properties and increase apoptosis. This evidence concerns the gene POLR1B and cancer.